Intended for healthcare professionals


Covid-19: Valneva’s vaccine produces stronger immune response than AstraZeneca’s, company reports

BMJ 2021; 375 doi: (Published 18 October 2021) Cite this as: BMJ 2021;375:n2551

Read our latest coverage of the coronavirus pandemic

  1. Elisabeth Mahase
  1. The BMJ

Valneva’s covid-19 vaccine produces significantly higher concentrations of neutralising antibodies than the Oxford-AstraZeneca vaccine does, preliminary trial results show.

The phase III trial included just over 4000 adult volunteers across 26 sites in the UK, of whom 1040 under 30s and 1977 over 30s received Valneva’s vaccine and 995 over 30s were given AstraZeneca’s.

In a press release Valneva reported that the trial met its primary endpoints, with the vaccine showing superiority over the AstraZeneca vaccine in terms of neutralising antibody concentrations and was non-inferior in terms of seroconversion rates (above 95% in both groups), two weeks after the second dose in the over 30s.1

Valneva is a French company that specialises in vaccine development, with …

View Full Text

Log in

Log in through your institution


* For online subscription